Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PKB-171
- Development stage
- Preclinical
- Lead developer
- Prokrea BCN
- Modality
- Small Molecules
- Administration
- Vaginal
01
Overview
PKB-171 is a preclinical-stage small molecule therapeutic being developed by Prokrea for the treatment of mild male factor infertility and sperm motility impairment. It consists of a repositioned formulation of pentoxifylline, delivered as a post-coital vaginal gel. Pentoxifylline acts as a non-selective phosphodiesterase inhibitor, which increases intracellular levels of cyclic adenosine monophosphate (cAMP). In the context of infertility, this mechanism enhances sperm motility and metabolic activity, potentially facilitating fertilization by improving the ability of sperm to reach and penetrate the egg within the female reproductive tract.
- Other names
- pentoxifylline vaginal gelpentoxifylline
Beyond the preview
Go deeper on PKB-171.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PKB-171.